Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Core Insights - Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel molecular glue degrader (MGD)-based medicines for serious diseases [3] Company Overview - Monte Rosa is developing highly selective MGD medicines targeting oncology, autoimmune, and inflammatory diseases [3] - The company's QuEEN™ discovery engine utilizes AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets [3] - Monte Rosa has a leading pipeline of MGDs and has established a global license agreement with Novartis for VAV1-directed MGDs, along with a strategic collaboration with Roche for MGDs targeting cancer and neurological diseases [3] Upcoming Events - CEO Markus Warmuth will present at the TD Cowen 45th Annual Health Care Conference on March 3, 2025, at 2:30 p.m. EST [1] - A webcast of the presentation will be available on Monte Rosa's website, with an archived version accessible for 30 days post-presentation [2]